News
AVLN
29.73
+3.52%
1.01
Weekly Report: what happened at AVLN last week (0713-0717)?
Weekly Report · 4d ago
Weekly Report: what happened at AVLN last week (0706-0710)?
Weekly Report · 07/13 10:37
Weekly Report: what happened at AVLN last week (0629-0703)?
Weekly Report · 07/06 10:42
Weekly Report: what happened at AVLN last week (0622-0626)?
Weekly Report · 06/29 10:36
Weekly Report: what happened at AVLN last week (0615-0619)?
Weekly Report · 06/22 10:48
Avalyn Pharma completes target enrollment in MIST trial
TipRanks · 06/17 12:15
Avalyn Pharma completes enrollment in Phase 2b MIST trial of inhaled pirfenidone for progressive pulmonary fibrosis
PUBT · 06/17 12:02
AVALYN COMPLETES TARGET ENROLLMENT IN PHASE 2B MIST TRIAL OF AP01 (INHALED PIRFENIDONE) FOR PATIENTS WITH PROGRESSIVE PULMONARY FIBROSIS
Reuters · 06/17 12:00
AVALYN PHARMA - TOPLINE DATA FROM MIST TRIAL EXPECTED IN SECOND HALF OF 2027
Reuters · 06/17 12:00
Weekly Report: what happened at AVLN last week (0608-0612)?
Weekly Report · 06/15 10:48
Weekly Report: what happened at AVLN last week (0601-0605)?
Weekly Report · 06/08 10:42
Avalyn Pharma Outlines Inhaled Fibrosis Push After IPO, With Pivotal Data Ahead
Barchart · 06/05 21:06
Analysts Are Bullish on These NA Stocks: MiniMed Group, Inc. (MMED), Avalyn Pharma Inc (AVLN)
TipRanks · 06/04 10:50
Avalyn Pharma reports Q1 results
Seeking Alpha · 06/03 11:39
Avalyn Pharma FY26 Q1 net loss widens to $26.87 million
PUBT · 06/03 11:02
AVALYN REPORTS FIRST QUARTER 2026 FINANCIAL RESULTS AND RECENT BUSINESS HIGHLIGHTS
Reuters · 06/03 11:00
Avalyn: Q1 Earnings Snapshot
Barchart · 06/03 07:07
Weekly Report: what happened at AVLN last week (0525-0529)?
Weekly Report · 06/01 10:49
Opening Day: SpaceX submits S-1 for Nasdaq IPO
TipRanks · 05/26 16:06
Avalyn Pharma initiated with an Overweight at Morgan Stanley
TipRanks · 05/26 09:21
More
Webull provides a variety of real-time AVLN stock news. You can receive the latest news about AVALYN PHARMACEUTICALS INC through multiple platforms. This information may help you make smarter investment decisions.
About AVLN
Avalyn Pharma Inc. is a clinical-stage biopharmaceutical company engaged in inhaled therapies to transform the treatment paradigm of serious, rare respiratory diseases with significant unmet needs. The Company's pipeline is focused on treating pulmonary fibrosis. It has three approved oral antifibrotic therapies for pulmonary fibrosis: pirfenidone; nintedanib, and nerandomilast. Its clinically advanced candidates, AP01 and AP02, are inhaled formulations of pirfenidone and nintedanib for the treatment of progressive pulmonary fibrosis and idiopathic pulmonary fibrosis, respectively. It has completed ATLAS, a Phase 1b clinical trial of AP01 in patients with IPF. AP02 is being evaluated in AURA, a global Phase II clinical trial for the treatment of IPF. It is also advancing AP03 into a Phase I clinical trial. AP03 is a fixed-dose combination of inhaled pirfenidone, and nintedanib designed to deliver dual antifibrotic mechanisms with the potential for additive or synergistic benefit.